ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation

Courtesy of Dr. Carlos Fava.

In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function. 

MITRA FR: el testeo del MitraClip en las insuficiencias mitrales funcionalesAt present, prognosis is based on ventricular function and the regular course of action is optimal medical treatment. Even though some studies have shown edge-to-edge percutaneous repair with MitraClip seems to improve symptoms, functional class and 6-minute walk test results, it has not been tested yet in large randomized studies.

 

This randomized study included patients with secondary mitral valve regurgitation with effective regurgitant orifice area of >20 mm2 or a regurgitant volume of >30 ml per beat, ejection fraction between 15 and 40%, and functional class II-III-IV.

 

It included 152 patients receiving MitraClip + medical treatment vs. 152 receiving only medical treatment.


Read also: ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention.


Primary end point was all cause death and unplanned hospitalization for cardiac failure at 12 months.

 

Mean age was 70 (patients were mostly men); ejection fraction was 33%; effective regurgitation area was 33 mm2; regurgitant volume was 45 ml; and EuroSCORE was 6.

 

Implantation success was 95.8%, and in 75.6% of patients, MR was 0 or 1+.


Read also: ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction.


At 12-month follow up, primary end point was 56.4% in patients undergoing percutaneous repair and 51.3% in the medical treatment group (odds ratio, 1.16; 95% confidence interval [CI], 0.73 to 1.84; P = 0.53). All-cause mortality was 24.3% vs. 22.4% (hazard ratio, 1.11; 95% CI, 0.69 to 1.77) and unplanned hospitalization was 48.7% vs. 47.4% (hazard ratio, 1.13; 95% CI, 0.81 to 1.56).

 

Conclusion

Among patients with secondary mitral regurgitation, death or unplanned hospitalization rate for cardiac failure at one year does not significantly differ between patients receiving percutaneous repair with medical treatment and patients receiving medical treatment alone.

 

Comment

In this randomized study, there was no benefit in terms of mortality or unplanned hospitalization for cardiac failure. This might be a consequence of ventricular function deterioration caused by severe ischemia and/or necrosis which, as we all know, is a negative predictor; this in addition to a medical treatment indeed optimal.

 

We’ll be looking forward to the long-term outcomes. We should also know more about the drugs involved, and assess functional class and 6-minute walk results.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.

Reference: J.-F. Obadia, Et Al. For the MITRA-FR Investigators. NEJM DOI: 10.1056/NEJMoa1805374.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...